Comparative Immunogenicity of Human Immunodeficiency Virus Particles and Corresponding Polypeptides in a DNA Vaccine

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2004 Dec 15

PMID 15596858

Citations 3

Authors

Wataru Akahata

Zhi-Yong Yang

Gary J Nabel

Affiliations

Soon will be listed here.

Abstract

The immunogenicity of a plasmid DNA expression vector encoding both Gag and envelope (Env), which produced human immunodeficiency virus (HIV) type 1 virus-like particles (VLP), was compared to vectors expressing Gag and Env individually, which presented the same gene products as polypeptides. Vaccination with plasmids that generated VLP showed cellular immunity comparable to that of Gag and cell-mediated or humoral responses similar to those of Env as immunization with separate vectors. These data suggest that DNA vaccines encoding separated HIV polypeptides generate immune responses similar to those generated by viral particles.

Citing Articles

A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection.

Akahata W, Yang Z, Andersen H, Sun S, Holdaway H, Kong W Nat Med. 2010; 16(3):334-8.

PMID: 20111039 PMC: 2834826. DOI: 10.1038/nm.2105.

Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag.

Santos K, Duke C, Rodriguez-Colon S, Dakwar A, Fan S, Keefer M Vaccine. 2006; 25(9):1634-46.

PMID: 17145123 PMC: 1851942. DOI: 10.1016/j.vaccine.2006.11.004.

Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif.

Eda Y, Takizawa M, Murakami T, Maeda H, Kimachi K, Yonemura H J Virol. 2006; 80(11):5552-62.

PMID: 16699036 PMC: 1472165. DOI: 10.1128/JVI.02094-05.

References

Attal J, Theron M, Kann G, Bolifraud P, Puissant C, Houdebine L . The stimulation of gene expression by the R region from HTLV-1 and BLV. J Biotechnol. 2000; 77(2-3):179-89. DOI: 10.1016/s0168-1656(99)00221-7. View

Akahata W, Ido E, Shimada T, Katsuyama K, Yamamoto H, Uesaka H . DNA vaccination of macaques by a full genome HIV-1 plasmid which produces noninfectious virus particles. Virology. 2000; 275(1):116-24. DOI: 10.1006/viro.2000.0486. View

Gorelick R, Benveniste R, Lifson J, Yovandich J, Morton W, Kuller L . Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost. J Virol. 2000; 74(24):11935-49. PMC: 112477. DOI: 10.1128/jvi.74.24.11935-11949.2000. View

Mariani R, Rasala B, RUTTER G, Wiegers K, BRANDT S, Krausslich H . Mouse-human heterokaryons support efficient human immunodeficiency virus type 1 assembly. J Virol. 2001; 75(7):3141-51. PMC: 114108. DOI: 10.1128/JVI.75.7.3141-3151.2001. View

Huang Y, Kong W, Nabel G . Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J Virol. 2001; 75(10):4947-51. PMC: 114253. DOI: 10.1128/JVI.75.10.4947-4951.2001. View

Maecker H, Dunn H, Suni M, Khatamzas E, Pitcher C, Bunde T . Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods. 2001; 255(1-2):27-40. DOI: 10.1016/s0022-1759(01)00416-1. View

Betts M, Ambrozak D, Douek D, Bonhoeffer S, Brenchley J, Casazza J . Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol. 2001; 75(24):11983-91. PMC: 116093. DOI: 10.1128/JVI.75.24.11983-11991.2001. View

Chen B, Rousso I, Shim S, Kim P . Efficient assembly of an HIV-1/MLV Gag-chimeric virus in murine cells. Proc Natl Acad Sci U S A. 2001; 98(26):15239-44. PMC: 65013. DOI: 10.1073/pnas.261563198. View

Chertova E, Bess Jr J, Crise B, Sowder II R, Schaden T, Hilburn J . Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol. 2002; 76(11):5315-25. PMC: 137021. DOI: 10.1128/jvi.76.11.5315-5325.2002. View

10.

Chakrabarti B, Kong W, Yang Z, Friborg J, Ling X, King S . Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol. 2002; 76(11):5357-68. PMC: 137015. DOI: 10.1128/jvi.76.11.5357-5368.2002. View

11.

Sheehy A, Gaddis N, Choi J, Malim M . Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002; 418(6898):646-50. DOI: 10.1038/nature00939. View

12.

Huang Y, Xu L, Sun Y, Nabel G . The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol Cell. 2002; 10(2):307-16. DOI: 10.1016/s1097-2765(02)00588-9. View

13.

Willey R, Byrum R, Piatak M, Kim Y, Cho M, Rossio Jr J . Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particles. J Virol. 2002; 77(2):1163-74. PMC: 140830. DOI: 10.1128/jvi.77.2.1163-1174.2003. View

14.

Lu W, Wu X, Lu Y, Guo W, Andrieu J . Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med. 2002; 9(1):27-32. DOI: 10.1038/nm806. View

15.

Akahata W, Ido E, Akiyama H, Uesaka H, Enose Y, Horiuchi R . DNA vaccination of macaques by a full-genome simian/human immunodeficiency virus type 1 plasmid chimera that produces non-infectious virus particles. J Gen Virol. 2003; 84(Pt 8):2237-2244. DOI: 10.1099/vir.0.19082-0. View

16.

Trigona W, Clair J, Persaud N, Punt K, Bachinsky M, Sadasivan-Nair U . Intracellular staining for HIV-specific IFN-gamma production: statistical analyses establish reproducibility and criteria for distinguishing positive responses. J Interferon Cytokine Res. 2003; 23(7):369-77. DOI: 10.1089/107999003322226023. View

17.

Kong W, Huang Y, Yang Z, Chakrabarti B, Moodie Z, Nabel G . Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol. 2003; 77(23):12764-72. PMC: 262562. DOI: 10.1128/jvi.77.23.12764-12772.2003. View

18.

Yang Z, Chakrabarti B, Xu L, Welcher B, Kong W, Leung K . Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope. J Virol. 2004; 78(8):4029-36. PMC: 374252. DOI: 10.1128/jvi.78.8.4029-4036.2004. View

19.

Yang Z, Huang Y, Ganesh L, Leung K, Kong W, Schwartz O . pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol. 2004; 78(11):5642-50. PMC: 415834. DOI: 10.1128/JVI.78.11.5642-5650.2004. View

20.

Daniel M, Kirchhoff F, Czajak S, Sehgal P, Desrosiers R . Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 1992; 258(5090):1938-41. DOI: 10.1126/science.1470917. View